Castration-Resistant Prostate Cancer: CC-1 Antibody Study

We are testing a new bispecific antibody for patients with castration-resistant prostate cancer. The study aims to evaluate its safety and how well it may work compared to existing treatments.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Charite Universitaetsmedizin Berlin KöR
Charité Benjamin Franklin Onkologische Studienzentrale
Teltow, Germany
Universitaetsklinikum Tuebingen AöR
KKE Translationale Immunologie Tübingen
Tübingen, Germany
Sponsor: Universitaetsklinikum Tuebingen AöR
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.